Advancing Ulixacaltamide for Essential Tremor: Essential3, an At-Home Research Study

At home, it’s easier to manage essential tremor. We designed a study to meet you there.​ Learn more about the Essential3 Study.

Learn more about the Essential3 Study for Adults Diagnosed with Essential Tremor

The Essential3 study has been designed so that you may participate from the comfort of your own home. Learn more about how this fully decentralized study is implemented.

Let’s talk about Essential Tremor

Praxis is excited to share with the essential tremor community that we collaborated with the Lifetime television show, The Balancing Act, to raise awareness about essential tremor and its impact on patients’ daily lives.

DARE FOR MORE™ in Essential Tremor: Ulixacaltamide Study Findings

We are excited to share the Essential1 topline data with the essential tremor (ET) community: Results show potential for ulixacaltamide (previously PRAX-944) to transform the treatment of essential tremor (ET).

For more information on essential tremor awareness, education, support and research please visit the International Essential Tremor Foundation (IETF)

We use cookies to improve your experience and to help us understand how you use our site. Please refer to our cookie notice and privacy statement for more information regarding cookies and other third-party tracking that may be enabled.

For more information on Praxis, including our privacy policy, visit us at If you have any questions, please email us at

© 2023 Praxis Precision Medicines, Inc.

Twitter icon
YouTube icon
LinkedIn icon
Website icon
Facebook icon
Intuit Mailchimp logo